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Abstract 
 
 
 
 
 
 
 
As a 5-α reductase inhibitor, Finasteride has proven effective in ameliorating two 
conditions documented to be androgen dependent, namely male androgenic alopecia and 
benign prostatic hyperplasia. Therapeutic results are maintained as long as the drug is 
administered, with treatment cessation generally leading to the return of symptomatology 
for each condition. In addition, during the therapeutic phase, several adverse effects have 
been reported, some of which persist long or indefinitely after treatment cessation, known as 
“post-finasteride syndrome.” 
Herein we present and discuss the most common finasteride side effects, along with a 
psycho-neuroendocrine rationale that could explain the persistence of many adverse effects 
after treatment cessation. Moreover, we argue that finasteride adverse effects occurring 
during finasteride administration should be delineated from postfinasteride side effects 
(encountered after treatment cessation), suggesting the need to be addressed separately 
within a therapeutic perspective. Until a tailored therapeutic approach of postfinasteride 
syndrome becomes available, we have noted that hand preference and sexual orientation 
seem to be useful as possible predicting factors for finasteride side effects and 
postfinasteride syndrome. 
Finally, even though finasteride administration is considered relatively safe, literature 
data urges prudence. Specifically, recent studies report that some subjects receiving 
finasteride develop severe depressive episodes including suicidal thoughts, in part due to 
persistent sexual side effects. 
  
Keywords: finasteride, adverse effects, post-finasteride syndrome, mental disorders, 
sexual dysfunctions   
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Introduction 
Finasteride is an extensively used medication 
for treatment of male pattern hair loss and benign 
prostatic hyperplasia. It is a type II and type III 
inhibitor of 5-α reductase, an enzyme that converts 
testosterone, progesterone and deoxycorticosterone 
to their corresponding metabolites. Even though 
therapeutic efficacy has been demonstrated through 
several studies, the research literature describes 
multiple adverse effects occurring during 
therapeutic phase (1, 2). Moreover, for some 
subjects, these effects have been described as “post-
finasteride” syndrome, consisting in signs and 
symptoms that continue after treatment cessation (at 
three months or more) and that are related 
particularly to mental and sexual side effects 
(depression, anxiety, suicidal thoughts, erectile and 
orgasmic troubles, etc.) (3). Other adverse effects of 
postfinasteride syndrome are represented mostly by 
physical impairments, consisting in gynecomastia, 
chronic fatigue, increased fat deposition, secondary 
infertility, etc (4, 5). 
Testosterone, progesterone, deoxycortico-
sterone (and their corresponding metabolites) act as 
neurosteroids within the brain, being at least in part 
responsible for finasteride side effects and 
postfinasteride syndrome (6). Taking into account 
that cerebral activation through neurosteroids is 
generally related to lateralized process of the brain, 
finasteride adverse effects actually demonstrate a 
predictability related to hand preference and sexual 
orientation (7, 8). Regarding the therapeutic 
approach to postfinasteride syndrome, no specific 
therapy is yet agreed upon or recommended, current 
approaches being intended to address the specific 
signs and symptoms rather than taking the approach 
of addressing the issue as a broader neuro-
endocrine disorder (9).   
 
Discussion 
Male androgenic alopecia is a moderately 
stressful condition that often warrants medical 
treatment, due to alteration of body image 
satisfaction. Benign prostatic hyperplasia (BPH/ 
benign enlargement of the prostate) is a relatively 
common condition in elderly men, being 
represented by a variable increase in volume of the 
prostate through prostatic hyperplasia. Both 
conditions are closely related to/ favored by action 
of dihydrotestosterone (DHTT). As a consequence, 
compounds interfering with DHTT synthesis 
(finasteride, dutasteride) have been investigated and 
introduced in clinical practice as therapeutic 
possibilities for these two conditions (10, 11).  
Therapeutic approaches  
Finasteride was initially approved for 
treatment of benign prostatic hyperplasia; five years 
later it was recognized for the second indication as 
a therapeutic approach for male androgenic alopecia 
(12).   
Regarding benign prostatic hyperplasia, 
physicians usually prescribe 5 mg finasteride/day, 
which has proven effective in ameliorating specific 
symptoms related to prostate enlargement, such as 
night time and difficult urination (decreased flow, 
prolonged initiation etc.). These positive effects can 
be obtained after six months or more from 
finasteride administration; however, these 
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therapeutic results typically cease after finasteride 
cessation (at variable periods of time) (13).   
Regarding androgenic alopecia, finasteride is 
recommended only in men. It is not approved for 
use in women due to risks of birth defects in the 
fetus. At a dose of 1 mg/ day, finasteride provides 
up to 20-30% improvement in hair loss after about 
six months of treatment. However, as in the case of 
benign prostatic hyperplasia, therapeutic benefits 
are maintained only so long as the drug is 
administered (14).  
Thus, therapeutic recommendations of 
finasteride imply administration of the drug for a 
considerable period of time (six months or more, to 
become effective), for both benign prostatic 
hyperplasia and androgenic alopecia. During this 
prolonged period, several neuroendocrine 
imbalances occur, which form the basis for 
finasteride and postfinasteride adverse effects.      
Pharmacology 
Finasteride is a type II and type III inhibitor of 
5-α reductase, an enzyme that converts testosterone, 
progesterone and deoxycorticosterone to their 
corresponding metabolites, represented by 
dihydrotestosterone, dihydroprogesterone, and 
dihydrodeoxycorticosterone respectively. Due to 
this action, the serum level of DHTT decreases after 
administration of 1 mg/day finasteride by about 65–
70%, and up to 85–90% after 5 mg/ day finasteride 
administration (15, 16). Finasteride does not 
completely suppress 5-α reductase and DHTT 
synthesis, in contrast to dutasteride that, by 
inhibiting all three isoforms of 5α-reductase 
enzyme, decreases the DHTT plasmatic level up to 
95- 99% (17).  In addition to inhibition of type II 
and III of 5-α reductase isoenzymes, finasteride 
inhibits type II of the 5β-reductase isoenzyme, 
which also interferes in androgen metabolism (18). 
In humans, the 5a reductase isoenzymes are 
encountered in several tissues including brain, 
prostate, skin/ hair follicles, liver, seminal vesicles, 
testicles, and gastrointestinal tract (19).  
Centrally, DHTT intervenes in metabolism of 
testosterone, progesterone and deoxycorticosterone, 
known as active neurosteroids able to interfere with 
the activation of the GABAA receptors in the brain 
(20). Hormonal abnormalities and GABA 
disruption induced by Finasteride administration are 
encountered in formerly-treated patients as well. 
Such men exhibit (at variable periods of time after 
the therapy) persistent disturbed levels of several 
active neurosteroids in cerebrospinal fluid and 
plasma: increased testosterone, 5a-androstane-3a, 
17b-diol, pregnenolone, and decreased 
dihydrotestosterone, progesterone, dihydropro-
gesterone and allopregnanolone (21).  
Adverse effects 
The cerebral actions of finasteride (via 
hormones and GABA transmission) are usually 
responsible for most finasteride adverse effects, 
while peripheral effects (reducing androgen activity 
in the scalp and prostate) are responsible for its 
therapeutic action. Regarding finasteride side 
effects, these manifestations are the consequence of 
indirect actions of the drug within the brain 
(through hormonal imbalances, GABA, and other 
possible/ unknown mechanisms) that add to other 
adverse effects resulting from the direct action of 
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finasteride on the brain and peripheral organs 
(nausea, vomiting, allergies, etc.) (22).   
Hormonal abnormalities and GABA 
imbalances induced by Finasteride are encountered 
in some patients after the therapy as persistent 
neuroendocrine disorders. As a consequence, 
finasteride side effects (as clinical expression of 
neuroendocrine disorders) are also encountered 
after drug discontinuation, in the form of so-called 
post-finasteride syndrome. The most frequent 
manifestations of post-finasteride syndrome are 
represented by sexual disorders (impotence, erectile 
dysfunction, decreased libido, ejaculation disorders) 
and mental/psychological impairments (depression, 
suicidal ideations, anhedonia, lack of mental 
concentration, etc.) (23). Other less common 
adverse effects are represented by: insomnia, 
premenstrual and postpartum dysphoric disorder, 
catamenial epilepsy, physical impairments 
(gynecomastia/ female-like enlargement of the 
breast, chronic fatigue, muscle twitching and 
atrophy, decreased body temperature, increased fat 
deposition/ elevated body mass index), 
cardiovascular impairments (palpitations, 
hypotension), dermatologic and oral manifestations 
(chronically dry, pruritus, rash, urticaria, erythema, 
purpura, gingival hypertrophy) (24). In addition, 
finasteride administration may affect tolerance to 
ethanol, with many former users of finasteride 
noting decreased tolerance for alcohol and 
disturbing effects from alcohol consumption (some 
men cease drinking completely) (25).       
Finally, reducing the risk of prostate cancers 
dependent on androgens (namely low-grade 
prostate cancers) is due to DHTT decreasing, yet 
finasteride administration is associated to a greater 
extent with high-grade prostate cancers (which 
seem unrelated in its progression to androgens) (26, 
27). In addition, finasteride lowers the PSA 
(prostate-specific antigen), which can be a serious 
impediment to the early detection of the prostate 
cancer (28). Although the incidence of male breast 
cancer has not increased from clinical trials (after 5 
mg finasteride, daily), there have been case reports 
of breast cancer in men taking finasteride. Yet, 
studies indicate no causative relationship between 
finasteride administration and male breast cancer 
(29, 30). Preliminary studies on women show that 
5-α reductase inhibitors induce sexual side effects 
also in women, even if this was reported in a lower 
extent (31).     
The persistence of adverse effects 
As noted above, the most frequent 
manifestations of post-finasteride syndrome are 
represented by sexual disorders and mental 
impairments.  
Multiple interrelations exist between 
cognition and sexuality, due to the fact that both 
functions arise from the same set of environmental 
stimuli, peripherally sharing common somatic 
afferents as well as centrally sharing a common/ 
mental operator for environmental tasks (32, 33). 
These psychophysiologic/ neuroendocrine 
interrelations between cognition and sexuality are 
bidirectional such that, when are disturbed, they 
often generate a vicious neuro-endocrine 
reciprocating process (between depression for 
example, and sexual dysfunctions), with each being 
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able to maintain or to intensify the other (34). 
According to several studies, the postfinasteride 
syndrome is irreversible in some patients (35, 36).    
Such looped mechanism could perhaps explain 
the persistence of finasteride side effects in the form 
of postfinasteride syndrome. Due to such 
bidirectional interferences, depression and sexual 
dysfunctions seem to be frequently associated, not 
only after finasteride administration but also in a 
multitude of other distinct situations (34, 37, 38).  
The lateralized process of finasteride, in respect 
to biochemical action and adverse effects 
The levels of dihydrotestosterone, dihydro-
progesterone and dihydrodeoxycorticosterone 
decrease substantially in all men receiving 
Finasteride, effects found in both cerebrospinal 
fluid and plasma (21). Contrasting with this 
biochemical action, finasteride adverse effects are 
encountered only in a subset of men (39), most 
probably due to lateralization processes of the brain 
(40).  
Based on several clinical studies, finasteride 
appears to decrease sexual function predominantly 
in right handed men (7, 8, 39, 40). In contrast, 
tamoxifen seems to induce adverse reactions 
(sexual side effects and depression) to a greater 
extent in left-handed men (41). In addition, 
imagistic studies with fRMI suggest that male 
sexual pheromones have an evident impact on 
homosexual men, activating predominantly the left 
hemibrain (left angular gyrus, left amygdala, left 
caudate nucleus, etc.). In contrast, yet in some way 
paralleling hormone effects, female sexual 
pheromones have an impact on heterosexual men 
(opposite orientation), activating in particular the 
right hemibrain, that is, the opposite hemisphere, 
including right hippocampus, right amygdala, right 
parahippocampal gyrus, etc.) (42- 44).  
Extrapolating from such findings, it appears 
that finasteride adverse effects might be correlated 
with both hand preference and sexual orientation of 
the men taking the drug. Given that no proven, 
documented therapeutic approach of postfinasteride 
syndrome currently exist, it may be worthwhile to 
use hand preference and sexual orientation as 
possible predicting conditions for adverse effects so 
as to identify prior to therapy those subjects having 
a higher chance of developing such effects, should 
they receive finasteride (7, 8). 
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Conclusions 
Finasteride adverse effects (encountered during 
the drug administration) persist long afterward in 
some patients, the so-called postfinasteride 
syndrome (residual side effects). Even so, 
postfinasteride side effects must be viewed as 
distinct from finasteride adverse effects, at least due 
to two important grounds. First, finasteride adverse 
effects related to the direct presence/ action of the 
drug (nausea, postural hypotension, urticaria, rash, 
David L. Rowland. et al. 
104 
 
etc.) cease after finasteride cessation. Second, many 
adverse effects that are induced due to indirect 
action of finasteride (via hormones and GABA 
receptors) persist after finasteride cessation. This 
suggests that finasteride merely triggers/ initiates 
the respective neuroendocrine disorders, which then 
have the capacity to self-maintain over time, 
eventually even evolving towards new and more 
complex neuroendocrine imbalances (not 
necessarily related to finasteride). For these reasons, 
we recommend that finasteride adverse effects and 
postfinasteride syndrome be addressed separately, 
as they belong to distinct pathophysiological 
entities and therefore require perhaps distinct 
therapeutic approaches.   
Even though the general perspective is that 
finasteride administration is relatively safe, the 
research literature urges prudence. Thus, recent 
studies report that some subjects treated with 
finasteride for androgenic alopecia can develop 
severe depressive symptoms and even suicidal 
thoughts, in part due to persistent sexual side effects 
(9, 45). These adverse effects related to Finasteride/ 
postfinasteride are yet under study, a quite difficult 
evaluation due to the fact that both mental and 
sexual functions (usually affected in tandem by 
Finasteride) are still incompletely described from 
clinical and psychophysiological perspectives. In 
addition, the postfinasteride syndrome has been 
described and recognized only relatively recently, 
thus requiring further study regarding 
symptomatology and the best therapeutic approach 
(46).  
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